SOUTH SAN FRANCISCO, Calif., May 06, 2024--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual ...
SOUTH SAN FRANCISCO, Calif., April 21, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from its market-leading Decipher Prostate ...
Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology SOUTH SAN ...
SOUTH SAN FRANCISCO, Calif. - Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company with a market capitalization of $2.51 billion and impressive revenue growth of 23.46% in the last twelve ...
A new at-home spit test for prostate cancer may be better than current blood tests, a new study shows. The simple saliva test has been developed by experts and works by analysing genetic variants in a ...
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback